Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 136,000 | 207,571 | 159,933 | 166,496 | 139,000 |
| Cost of Goods | 30,000 | 29,007 | 27,991 | 23,002 | 29,000 |
| Gross Profit | 106,000 | 178,564 | 131,942 | 143,494 | 110,000 |
| Operating Expenses | 275,000 | 291,793 | 303,823 | 251,384 | 253,000 |
| Operating Income | -169,000 | -113,222 | -170,890 | -107,888 | -143,000 |
| Interest Expense | 21,000 | 19,811 | 14,148 | 14,041 | 14,000 |
| Other Income | 6,000 | 5,577 | 5,498 | 7,925 | 7,000 |
| Pre-tax Income | -184,000 | -127,456 | -179,540 | -114,004 | -150,000 |
| Income Tax | 1,000 | 1,180 | 873 | 947 | 1,000 |
| Net Income Continuous | -185,000 | -128,636 | -180,413 | -114,951 | -151,000 |
| Net Income | $-185,000 | $-128,636 | $-180,413 | $-114,951 | $-151,000 |
| EPS Basic Total Ops | -1.84 | -1.28 | -1.81 | -1.17 | -1.57 |
| EPS Basic Continuous Ops | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 |
| EPS Diluted Total Ops | -1.84 | -1.28 | -1.81 | -1.17 | -1.57 |
| EPS Diluted Continuous Ops | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 |
| EPS Diluted Before Non-Recurring Items | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 |
| EBITDA(a) | $-162,000 | $-104,953 | $-162,988 | $-100,059 | $-136,000 |